Differential impacts of achieved heart rate and achieved dose of β-blocker on clinical outcomes in heart failure with and without atrial fibrillation

International Journal of Cardiology

Volumn 173, Issue 2, 2014, Pages 331-333

  Naoko, Kato ^a   Koichiro, Kinugawa ^a   Teruhiko, Imamura ^a   Hironori, Muraoka ^a   Hisataka, Maki ^a   Toshiro, Inaba ^a   Masaru, Hatano ^a   Atsushi, Yao ^a   Ryozo, Nagai ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b Jichii Medical University   (Japan)

Author keywords

Biomarker; Hospitalization; Mortality; Systolic heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL TARTRATE; WARFARIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

DRUG EFFICACY; DRUG MECHANISM; ENERGY EXPENDITURE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; JAPANESE; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SINUS RHYTHM; AGED; ATRIAL FIBRILLATION; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; HEART FAILURE, SYSTOLIC; MALE; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ATRIAL FIBRILLATION; FEMALE; HEART FAILURE, SYSTOLIC; HEART RATE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84898878985     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.03.050     Document Type: Article

References (10)

1. M. Gheorghiade, N.M. Albert, and A.B. Curtis et al. Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF Congest Heart Fail 18 2012 9 17
2. N. Kato, K. Kinugawa, and T. Imamura et al. Trend of clinical outcome and surrogate markers during titration of beta-blocker in heart failure patients with reduced ejection fraction Circ J 77 2013 1001 1008
3. F.A. McAlister, N. Wiebe, J.A. Ezekowitz, A.A. Leung, and P.W. Armstrong Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure Ann Intern Med 150 2009 784 794
4. K. Fox, I. Ford, and P.G. Steg et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial Lancet 372 2008 817 821
5. D. Castagno, H. Skali, and M. Takeuchi et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program J Am Coll Cardiol 59 2012 1785 1795
6. I.C. Van Gelder, H.F. Groenveld, and H.J.G.M. Crijns et al. Lenient versus strict rate control in patients with atrial fibrillation N Engl J Med 362 2010 1363 1373
7. J.A. Joglar, A.P. Acusta, and N.H. Shusterman et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program Am Heart J 142 2001 498 501
8. P. Porapakkham, P. Porapakkham, H. Zimmet, B. Billah, and H. Krum B-type natriuretic peptide-guided heart failure therapy: a meta-analysis Arch Intern Med 170 2010 507 514
9. J.L. Januzzi Jr., S.U. Rehman, and A.A. Mohammed et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction J Am Coll Cardiol 58 2011 1881 1889
10. S. Masson, R. Latini, and I.S. Anand et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data Clin Chem 52 2006 1528 1538